drug

(redirected from drug binding)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to drug binding: protein binding

drug

noun alterant, analgesic, anesthetic, anesthetic agent, anodyne, antibiotic, chemical substance, curative preparation, medical preparation, medicament, medication, medicinal component, medicinal innredient, narcotic preparation, narcotic substance, opiate, painkiller, palliative, physic, prescription, remedy, sedative, soporific, stimulant, stupefacient
Associated concepts: adulterated drugs, dangerous drugs, drug addiction, habit-forming drug, influence of drugs, laaeling of drugs, poisonous drugs or chemicals, possession of drugs, preparation of drugs, prescription drugs, regulaaion of drugs, sale of drugs

drug

verb administer, anesthetize, anoint, apply a remedy, benumb, cure, deaden, desensitize, dose, dull, heal, inject, medicare, medicate, narcotize, numb, palliate, physic, poultice, prescribe, put to sleep, stun, stupefy, treat
Associated concepts: drug addicts
References in periodicals archive ?
During the docking of the wild and the mutants against the available compounds, only three mutants were generated which were proximal to the drug binding site, and were also reported to be lethal.
72 Ser222 11 Residues that reside in the drug binding site are indicated in bold.
SA proteins have three linearly arranged domains (I-III) with two major drug binding sites in the subdomains IIA (site I) and IIIA (site II), which are widely known as warfarin and diazepam binding sites in BSA, respectively (Ni et al.
Among the endogenous solutes retained in uremia, IS, IA, HA, and CMPF are recognized as the major inhibitors of drug binding in serum in uremia.
Their ability to deliver information about drug binding and protein stability is entirely complementary to Malvern s current products and to those in development.
For the section on qualitative and quantitative analysis, enantioselective chromatographic methods are presented as well as optical methods and CE-MS, while the final section deals with the pharmacology, pharmacokinetics and metabolic aspects of chiral drugs, devoting whole chapters to stereoselective drug binding and modeling chiral drug-receptor interactions.
This project has been technically challenging since we have needed to compute binding to a protein with more than 1,400 residues, which may well be the largest protein surface ever comprehensively sampled for drug binding calculations.
Neurion's Associate Director, Molecular Neurosciences, said, "The difficulty in designing GABA(A)-alpha2 receptor-selective drugs is the lack of understanding of what defines selective drug binding and efficacy with GABA(A) receptor subtypes.
Locus's proprietary core technology (LCT) rapidly identifies viable drug binding sites on the surface of proteins and directs the de novo assembly of fragments into small molecule product candidates.
Specifically, the Chematica(TM) component will provide three dimensional homology modelling, drug binding site identification and mapping techniques and proprietary databases such as StARLITe(TM) will identify corresponding tractable chemical hits and GPCR family chemotypes.
From such information, Locus scientists identify viable drug binding sites and computationally design and synthesize new drug molecules for the target protein.